Abstract:Background Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease with a poor prognosis in which synovitis induces progressive destruction of bones and joints, which leads to marked impairment of the activities of daily living.More timely and effective therapy for rheumatoid arthritis has contributed to increasing rates of clinical remission. However, progression of structural damage may still occur in patients who have satisfied remission criteria (1,2).Most RA patients who satisfied the remission criteria with normal findings on clinical and laboratory studies had imaging-detected synovitis may explain the observed discrepancy between disease activity and outcome in RA (3). Objectives To evaluate theeffects of double filtration plasmapheresis (DFPP) in combination with Leflunomide and methotrexate on magnetic resonance imaging (MRI)-detected inflammatory changes (synovitis and bone marrow edema) in early rheumatoid arthritis (RA) patients with high disease activity. Methods Sixty RA patients with high active disease of 6 months to3 years’ duration were randomized to DFPP group and no-DFPP group. All patients received leflunomide10mg, two times daily, plus methotrexate15mg orally once weekly. DFPP was performed in the DFPP group once 1-2 weeks for 3 sessions. The primary end point was the improvement in MRI-detected synovitis from baseline over 6 months. Secondary end point variables included Clinical remission in DAS28 and ACR20, ACR50, ACR70 and ACR90 responses for 6 consecutive months. Results The study achieved a significant reduction in synovitis compared with baseline, witha reduction of 7 in the median synovitis score from baseline to month 6in the DFPP group compared with 0 in the median synovitis score from baseline to month 6for the no-DFPP group (P<0.001). Synovitis scores in 48.39% (15/31)of the Patients in the DFPP group were 0 at month 6.Bone edema scores in 32.26% (10/31) of the Patients in the DFPP group were 0 at month 6. ACR20, ACR50, ACR70 and ACR90 responses for 6 consecutive months had been achieved in 100% of patients in the DFPP group, compared with 37.93%, 20.69%, 10.34%, 0% respectively, of patients in the no-DFPP group (P<0.001). DAS28 remissionfor 6 consecutive months was achieved in 100% of patients in the DFPP group, compared with 6.90%of patients in the no-DFPP group (P<0.001). Conclusions The combination of DFPP and DMARDs is superior to DMARDs alone for reducing MRI-detected signs of synovitis and bone edema in patients with early high active rheumatoid arthritis. The DFPP therapy enables a rapid and more complete suppression of inflammation in patients withearly high active rheumatoid arthritis. Nearly half of the patients (48.39%) who had received DFPP therapy achieved both clinical remission and imaging remission,a true remission. References Kirwan JR. Links between radiological change, disability, and pathology in rheumatoid arthritis.J Rheumatol 2001,28:881-886. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of Radiologic Damage in Patients With Rheumatoid Arthritis in Clinical Remission. Arthritis Rheum 2004; 50:36-42. Brown AK, Conaghan PG, Karim Z, Quinn M A, Ikeda K, Peterfy CG, et al. An Explanation for the Apparent Dissociation Between Clinical Remission and Continued Structural Deterioration in Rheumatoid Arthritis. Arthritis & Rheumatism 2008,58: 2958-2967. Disclosure of Interest None Declared

Association of the multi-biomarker disease activity score with arterial 18-fluorodeoxyglucose uptake in rheumatoid arthritis

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

THU0156 Response of Ra on MRI-detected Synovitis to Double Filtration Plasmapheresis

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

Multi-biomarker Disease Activity Score and Its Application in Rheumatoid Arthritis

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes

Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients

Articular 18Fluorodeoxyglucose Uptake Is Associated With Clinically Assessed Swollen Joint Count in Patients With Rheumatoid Arthritis

Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial

Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation

E058 Disease activity measurement in rheumatoid arthritis - simpler in not always better!

Model‐Based Meta‐Analysis Compares DAS28 Rheumatoid Arthritis Treatment Effects and Suggests an Expedited Trial Design for Early Clinical Development

Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study

Malondialdehyde Serum Levels in a Full Characterized Series of 430 Rheumatoid Arthritis Patients

P125 Can musculoskeletal ultrasound assessment change management decisions in rheumatoid arthritis patients with moderate disease activity?

Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis

Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus and Association with All‐Cause Mortality

Impact of Cumulative Inflammation, Cardiac Risk Factors, and Medication Exposure on Coronary Atherosclerosis Progression in Rheumatoid Arthritis

Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?

Multiple sclerosis disease activity, a multi-biomarker score of disease activity and response to treatment in multiple sclerosis